FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer

Share:

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer

Science

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.